Biotechnology & Life Sciences Global On demand · 24-48h

Global Induced Pluripotent Stem Cells Service Market Strategic Research Report

Global Induced Pluripotent Stem Cells Service Market Strateg…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Induced Pluripotent Stem Cells Service Market
$3.15B2025
10.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: iPSC Manufacturing Service, iPSC Reprogramming Service, iPSC Culture Service, iPSC Differentiation Service, iPSC Gene Editing Service, Other

By Application: Pharmaceutical Company, Laboratory, Scientific Research Institution

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Lonza, Thermo Fisher Scientific Inc., FUJIFILM Cellular Dynamics, Inc. (FCDI), Charles River Laboratories, Novo Holdings (Catalent, Inc), Creative Bioarray, Creative Biolabs, iXCells Biotechnologies, Creative Biogene, Axol Bioscience Ltd., Elixirgen Scientific, Inc., Cyagen, ALSTEM, uBriGene Biosciences International Co., NEXEL Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 112 pages
Market size 2025
$3.15B
Billion USD
Forecast CAGR
10.8%
2025-2032
Forecast 2032
$6.5B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Induced Pluripotent Stem Cells Service market size is predicted to grow from US$ 3,153 million in 2025 to US$ 6,381 million in 2032; it is expected to grow at a CAGR of 10.8% from 2026 to 2032.

Induced pluripotent stem cell (iPSC) services refer to a series of professional technologies and processes designed to reprogram pluripotent stem cells from adult cells (such as skin or blood cells). These cells can self-renew and differentiate into a variety of cell types, and have a wide range of application potential, including regenerative medicine, drug screening, and disease model construction. iPSC manufacturing services are the core of iPSC services, including the selection of cell sources and the implementation of cell reprogramming. Through precise induction technology, researchers can convert mature somatic cells into iPSCs. iPSC reprogramming services focus on using various methods (such as viral vectors, transfection, or small molecule compounds) to achieve cell reprogramming. These methods can effectively improve the efficiency of reprogramming and the safety of cells. Once iPSCs are generated, iPSC culture services become key. This service ensures that iPSCs grow under optimal conditions, maintain their pluripotency, and avoid differentiation. Next, iPSC differentiation services can be used to induce iPSCs to differentiate into specific cell types, such as neurons, cardiomyocytes, etc., to meet research and treatment needs. In addition, iPSC gene editing services enable researchers to make precise gene modifications in iPSCs, facilitating the study of gene function, disease mechanisms, and the development of personalized treatment plans. In summary, induced pluripotent stem cell services cover multiple aspects such as iPSC manufacturing, reprogramming, culture, differentiation, and gene editing, providing strong support for regenerative medicine and biomedical research.

Global key Induced Pluripotent Stem Cells Service players cover Lonza, Thermo Fisher Scientific Inc., FUJIFILM Cellular Dynamics, Inc. (FCDI), Charles River Laboratories, Novo Holdings (Catalent, Inc), etc.

This report presents a comprehensive overview of the global Induced Pluripotent Stem Cells Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • iPSC Manufacturing Service
  • iPSC Reprogramming Service
  • iPSC Culture Service
  • iPSC Differentiation Service
  • iPSC Gene Editing Service
  • Other

Segment by Application

  • Pharmaceutical Company
  • Laboratory
  • Scientific Research Institution

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Induced Pluripotent Stem Cells Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmaceutical Company, Laboratory, Scientific Research Institution evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Induced Pluripotent Stem Cells Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 10.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.15B
2025
Forecast
$6.5B
2032
CAGR
10.8%
2025–2032
Regions
5
global
Key companies
LonzaThermo Fisher Scientific Inc.FUJIFILM Cellular DynamicsInc. (FCDI)Charles River LaboratoriesNovo Holdings (CatalentInc)Creative Bioarray
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
iPSC Manufacturing ServiceiPSC Reprogramming ServiceiPSC Culture ServiceiPSC Differentiation ServiceiPSC Gene Editing ServiceOther
By Application
Pharmaceutical CompanyLaboratoryScientific Research Institution

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 iPSC Manufacturing Service
  • 3.1.3 iPSC Reprogramming Service
  • 3.1.4 iPSC Culture Service
  • 3.1.5 iPSC Differentiation Service
  • 3.1.6 iPSC Gene Editing Service
  • 3.1.7 Other
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmaceutical Company
  • 4.1.3 Laboratory
  • 4.1.4 Scientific Research Institution
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Lonza
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 FUJIFILM Cellular Dynamics, Inc. (FCDI)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Charles River Laboratories
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Novo Holdings (Catalent, Inc)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Creative Bioarray
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Creative Biolabs
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 iXCells Biotechnologies
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Creative Biogene
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Axol Bioscience Ltd.
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Elixirgen Scientific, Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Cyagen
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 ALSTEM
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 uBriGene Biosciences International Co.
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 NEXEL Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Induced Pluripotent Stem Cells Service market?
The global Induced Pluripotent Stem Cells Service market is estimated at US$ 3.15 billion in 2025 (base year) and is projected to reach US$ 6.38 billion by 2032.
What is the forecast CAGR for the Induced Pluripotent Stem Cells Service market?
The market is expected to grow at a CAGR of 10.8% from 2026 to 2032, expanding from US$ 3.15 billion in 2025 to US$ 6.38 billion in 2032, roughly 2.0 times its base-year value.
What is Induced Pluripotent Stem Cells Service?
Induced pluripotent stem cell (iPSC) services refer to a series of professional technologies and processes designed to reprogram pluripotent stem cells from adult cells (such as skin or blood cells). These cells can self-renew and differentiate into a variety of cell types, and have a wide range of application potential, including regenerative medicine, drug screening, and disease model construction. iPSC manufacturing services are the core of iPSC services, including the selection of cell sources and the implementation of cell reprogramming.
What are the main segments of the Induced Pluripotent Stem Cells Service market by type?
By type, the market is segmented into iPSC Manufacturing Service, iPSC Reprogramming Service, iPSC Culture Service, iPSC Differentiation Service, iPSC Gene Editing Service and Other.
Which applications drive demand in the Induced Pluripotent Stem Cells Service market?
Key applications covered include Pharmaceutical Company, Laboratory and Scientific Research Institution.
Who are the key players in the Induced Pluripotent Stem Cells Service market?
Key players profiled include Lonza, Thermo Fisher Scientific Inc., FUJIFILM Cellular Dynamics, Inc. (FCDI), Charles River Laboratories, Novo Holdings (Catalent, Inc), Creative Bioarray, Creative Biolabs and iXCells Biotechnologies, among 15 companies covered in total.
Which regions and countries are covered for Induced Pluripotent Stem Cells Service?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Induced Pluripotent Stem Cells Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmaceutical Company, Laboratory and Scientific Research Institution, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Induced Pluripotent Stem Cells Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.